Tuesday, August 4, 2015

BioLight in DES diagnostic collaboration with Ora

BioLight in DES diagnostic collaboration with Ora

June 15, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) has expanded its relationship with Ora Inc., with the signing of a collaboration agreement to advance the clinical, regulatory and commercial development of BioLight’s TeaRx multi-parameter diagnostic test for dry eye syndrome (DES). BioLight and Ora will jointly fund the clinical study and other activities required to obtain […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

BioLight units post positive study results

BioLight units post positive study results

February 2, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTC:BLGTY; TASE:BOLT) has released positive study results from two subsidiaries developing the CellDetect non-invasive test for detecting bladder cancer in urine and the TeaRx diagnostic tests for dry eye. CellDetect successfully achieved the study’s primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of […]

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

January 5, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB), Dipexium Pharmaceuticals (NASDAQ:DPRX) and The Joint Corp. (NASDAQ:JYNT) were included in Feltl & Co.’s 2015 Top Idea List released today. Analyst Ben Haynor rates TearLab at “strong buy” with a price target of $5. The stock closed at $2.58 on Friday. TearLab has first-mover advantage in point-of-care diagnostics for dry eye […]

TearLab reports interim results of DED prevalence study in UK

TearLab reports interim results of DED prevalence study in UK

September 4, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported interim results of a multi-center dry eye disease (DED) prevalence study being carried out in the UK at four National Health Service (NHS) hospitals.  The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED. Conducted under the auspices of the UK’s National […]

Mati Therapeutics gets another U.S. patent

Mati Therapeutics gets another U.S. patent

June 30, 2014 by · Leave a Comment 

Tweet Closely held Mati Therapeutics has received a U.S. patent covering its novel punctal plug delivery system for treatment of ocular indications (PPDS), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution. The patent is titled, “Nasolacrimal Drainage System Implants For Drug Therapy.” Mati is actively […]

Mati Therapeutics isn’t your traditional biotech startup

Mati Therapeutics isn’t your traditional biotech startup

June 10, 2014 by · Leave a Comment 

Tweet Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye drops. “Because of the Phase 2 trials conducted by QLT on this technology, we have a different risk-reward profile than a […]

TearLab posts 70% jump in Q1 revenue

TearLab posts 70% jump in Q1 revenue

May 8, 2014 by · Leave a Comment 

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totaled $4.2-million, up 70%, from $2.5-million a year ago. A total of 254 orders for TearLab systems were booked in the first quarter, of which 201 systems were under the company’s Masters Multi Unit Program, 40 were through its minimum use access programs, six were direct purchases […]

In conversation with Elias Vamvakas

In conversation with Elias Vamvakas

January 28, 2014 by · Leave a Comment 

Tweet As CEO of San Diego-based TearLab (NASDAQ:TEAR; TSX:TLB), eye care entrepreneur, Elias Vamvakas, has scored another home run with a medical device for the diagnosis and management of dry eye disease (DED). The TearLab Osmolarity System uses a novel lab-on-a-chip approach that requires less than 50 nanoliters of tear fluid in order to measure […]

TearLab included in Feltl’s 2014 Top Idea List

TearLab included in Feltl’s 2014 Top Idea List

January 2, 2014 by · Leave a Comment 

Tweet Feltl & Co. has released its 2014 Top Idea List, which included TearLab (NASDAQ:TEAR; TSX:TLB). Analyst Ben Haynor writes that TearLab has first-mover advantage in point-of-care diagnostics for dry eye disease (DED). The TearLab Osmolarity System is a lab-on-a-chip system that provides a quantitative measure (osmolarity) of DED in less than 30 seconds. He […]

Next Page »

Email Newsletters with Constant Contact
Google+